Japan approves Bristol-Myers' nivolumab, hep C combo; CMS tweaks Sunshine Act;

> Bristol-Myers Squibb's ($BMS) Opdivo (nivolumab), an immuno-oncology drug for advanced melanoma, has scored its first regulatory green light, grabbing Japanese approval. Release

> Japan has approved Bristol-Myers Squibb's ($BMS) next-gen hepatitis C cocktail, made up of Daklinza and Sunvepra. Release

> The Centers for Medicare & Medicaid Services (CMS) announced plans to enact changes to the Open Payments program, including the Sunshine exemption for continuing medical education. More

> AstraZeneca ($AZN) will hold a Twitter chat to answer questions about its home-delivery program. Blog

> Celgene's ($CELG) Imnovid, a multiple myeloma drug, was rejected by the Scottish Medicines Consortium despite the recognition of its ability to significantly improve chances of survival. Sanofi's ($SNY) Lemtrada and Roche's ($RHHBY) MabThera both received positive recommendations. Story

> Takeda Pharmaceutical is taking heat for publishing a 74-page report on a probe of a "misleading" ad for its Blopress high blood pressure medicine--exclusively in Japanese. More (sub. req.)

And Finally... Taiwan's Gala Television has been fined $200,000 for using the name of a Taiwanese pharmaceutical company as a title sponsor for a singing contest. News

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.